Abstract Hereditary angiopathy with nephropathy, aneurysms and muscle cramps (HANAC) syndrome is an autosomal dominant genetic disease caused by COL4A1 gene mutation, with major clinical manifestations of white matter lesion, aneurysm, retinal artery tortuosity, polycystic kidney, microscopic hematuria and muscle cramps. This article reports the clinical features and genotype of one toddler with HANAC syndrome caused by COL4A1 gene mutation. The boy, aged 1 year and 8 months, had an insidious onset, with the clinical manifestations of pyrexia and convulsion, white matter lesions in the periventricular region and the centrum semiovale on both sides, softening lesions beside the left basal ganglia, retinal arteriosclerosis, microscopic hematuria and muscle cramps. Whole exome sequencing revealed a pathogenic de novo heterozygous mutation in the COL4A1 gene, (NM_001845) c.4150+1(IVS46)G > T, and therefore, the boy was diagnosed with HANAC syndrome. COL4A1 gene mutation detection should be performed for children with unexplained white matter lesion, stroke, hematuria, polycystic kidney, cataract and retinal artery tortuosity or families with related history.
SHAN Li-Dan,PENG Jing,XIAO Hui et al. Clinical features and COL4A1 genotype of a toddler with hereditary angiopathy with nephropathy, aneurysms and muscle cramps syndrome[J]. CJCP, 2019, 21(8): 754-760.
SHAN Li-Dan,PENG Jing,XIAO Hui et al. Clinical features and COL4A1 genotype of a toddler with hereditary angiopathy with nephropathy, aneurysms and muscle cramps syndrome[J]. CJCP, 2019, 21(8): 754-760.
Plaisier E, Alamowitch S, Gribouval O, et al. Autosomal-dominant familial hematuria with retinal arteriolar tortuosity and contractures:a novel syndrome[J]. Kidney Int, 2005, 67(6):2354-2360.
[2]
Plaisier E, Gribouval O, Alamowitch S, et al. COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps[J]. N Engl J Med, 2007, 357(26):2687-2695.
[3]
Vahedi K, Kubis N, Boukobza M, et al. COL4A1 mutation in a patient with sporadic, recurrent intracerebral hemorrhage[J]. Stroke, 2007, 38(5):1461-1464.
[4]
Breedveld G, de Coo IF, Lequin MH, et al. Novel mutations in three families confirm a major role of COL4A1 in hereditary porencephaly[J]. J Med Genet, 2006, 43(6):490-495.
[5]
Matsumoto T, Miyakoshi K, Fukutake M, et al. Intracranial sonographic features demonstrating in utero development of hemorrhagic brain damage leading to schizencephaly-associated COL4A1 mutation[J]. J Med Ultrason (2001), 2015, 42(3):445-446.
[6]
Sibon I, Coupry I, Menegon P, et al. COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke[J]. Ann Neurol, 2007, 62(2):177-184.
[7]
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants:a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5):405-424.
[8]
Gould DB, Phalan FC, Breedveld GJ, et al. Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly[J]. Science, 2005, 308(5725):1167-1171.
[9]
Plaisier E, Chen Z, Gekeler F, et al. Novel COL4A1 mutations associated with HANAC syndrome:a role for the triple helical CB3[IV] domain[J]. Am J Med Genet A, 2010, 152A(10):2550-2555.
[10]
Coupry I, Sibon I, Mortemousque B, et al. Ophthalmological features associated with COL4A1 mutations[J]. Arch Ophthalmol, 2010, 128(4):483-489.
[11]
Smigiel R, Cabala M, Jakubiak A, et al. Novel COL4A1 mutation in an infant with severe dysmorphic syndrome with schizencephaly, periventricular calcifications, and cataract resembling congenital infection[J]. Birth Defects Res A Clin Mol Teratol, 2016, 106(4):304-307.
Alamowitch S, Plaisier E, Favrole P, et al. Cerebrovascular disease related to COL4A1 mutations in HANAC syndrome[J]. Neurology, 2009, 73(22):1873-1882.
[14]
Takenouchi T, Ohyagi M, Torii C, et al. Porencephaly in a fetus and HANAC in her father:variable expression of COL4A1 mutation[J]. Am J Med Genet A, 2015, 167A(1):156-158.
[15]
Gould DB, Phalan FC, van Mil SE, et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke[J]. N Engl J Med, 2006, 354(14):1489-1496.
[16]
Shah S, Ellard S, Kneen R, et al. Childhood presentation of COL4A1 mutations[J]. Dev Med Child Neurol, 2012, 54(6):569-574.
[17]
Bilguvar K, DiLuna ML, Bizzarro MJ, et al. COL4A1 mutation in preterm intraventricular hemorrhage[J]. J Pediatr, 2009, 155(5):743-745.
[18]
Shah S, Kumar Y, McLean B, et al. A dominantly inherited mutation in collagen IV A1(COL4A1) causing childhood onset stroke without porencephaly[J]. Eur J Paediatr Neurol, 2010, 14(2):182-187.
[19]
Tomotaki S, Mizumoto H, Hamabata T, et al. Severe hemolytic jaundice in a neonate with a novel COL4A1 mutation[J]. Pediatr Neonatol, 2016, 57(6):522-525.
[20]
Vahedi K, Alamowitch S. Clinical spectrum of type IV collagen (COL4A1) mutations:a novel genetic multisystem disease[J]. Curr Opin Neurol, 2011, 24(1):63-68.
[21]
Chabriat H, Joutel A, Dichgans M, et al. CADASIL[J]. Lancet Neurol, 2009, 8(7):643-653.
[22]
Hara K, Shiga A, Fukutake T, et al. Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease[J]. N Engl J Med, 2009, 360(17):1729-1739.
[23]
Jen J, Cohen AH, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS)[J]. Neurology, 1997, 49(5):1322-1330.
[24]
Hayashi G, Labelle-Dumais C, Gould DB. Use of sodium 4-phenylbutyrate to define therapeutic parameters for reducing intracerebral hemorrhage and myopathy in Col4a1 mutant mice[J]. Dis Model Mech, 2018, 11(7). pii:dmm034157.
[25]
Jones FE, Murray LS, McNeilly S, et al. 4-Sodium phenyl butyric acid has both efficacy and counter-indicative effects in the treatment of Col4a1 disease[J]. Hum Mol Genet, 2019, 28(4):628-638.
